The vitamin A metabolite retinoic acid (RA) regulates intestinal immune responses through immunomodulatory actions on intestinal dendritic cells (DCs) and lymphocytes. Here, we show that RA also controls the generation of gut-tropic migratory DC precursors, referred to as pre-mucosal DCs (pre-lDCs). Pre-lDCs express the gut trafficking receptor a4b7 and home preferentially to the intestines. They develop in the bone marrow (BM), can differentiate into CCR9 þ plasmacytoid DCs as well as conventional DCs (cDCs), but preferentially give rise to CD103 þ intestinal cDCs. Generation of pre-lDCs in vivo in the BM or in vitro is regulated by RA and RA receptor a (RARa) signaling. The frequency of pre-lDCs is reduced in vitamin A-deficient animals and in animals treated with RAR inhibitors. The results define a novel vitamin A-dependent, RA-regulated developmental sequence for DCs and identify a targeted precursor for CD103 þ cDCs in the gut.
INTRODUCTION
The maintenance of steady-state tolerance to commensal flora and the ability to rapidly clear pathogens in case of gut wall disruption require flexibility and sophistication in the mucosal immune system. Specialized antigen-presenting dendritic cells (DCs) in the gut wall and gut-associated lymphoid tissues (GALT) control the balance between intestinal immunity and inflammation. [1] [2] [3] [4] [5] [6] [7] [8] [9] It is now clear that vitamin A and its metabolite retinoic acid (RA) play critical roles in the local differentiation and function of intestinal DCs, especially the migratory CD103 þ populations. 10 RA programs CD103 þ DCs to upregulate retinaldehyde dehydrogenase (RALDH), the rate-limiting enzyme for conversion of vitamin A precursors into RA. 10 These mucosal DCs migrate to the draining mesenteric lymph nodes (MLNs) where they present RA along with processed antigen to T cells. 2, 4 RA imprints responding T cells with gut-homing properties 11 and, in the absence of danger signals, favors the induction of tolerogenic regulatory T cells 8 by suppressing memory/effector T-cell-mediated inhibition of Treg conversion from naive T cells. 12 Thus, RA plays a critical local role in intestinal DC function and immune regulation, but its involvement in the origin of intestinal DC precursors has not been studied.
Here, we describe a targeted gut-homing DC precursor, designated pre-mucosal DCs (pre-mDCs), whose development in the bone marrow (BM) is regulated by RA. Pre-mDCs are identifiable phenotypically as lineage À CD11c int B220 þ CCR9 À cells that express the intestinal-homing receptor a4b7. They can arise in vitro from CD11c int B220 þ BM precursors that lack both CCR9 and a4b7. Pre-mDCs give rise to CCR9 þ plasmacytoid DCs (pDCs) and to conventional DCs (cDCs), and home preferentially to the intestines in vivo. They are particularly efficient at generating CD103 þ cDCs in vitro and replenishing intestinal CD103 þ cDCs in vivo. RA signaling through RA receptor a (RARa) drives pre-mDC differentiation from BM progenitors, and the frequency of pre-mDCs was reduced in vitamin A-deficient animals and in animals treated with an inhibitor of RAR signaling. RA thus plays a unifying role in intestinal DC development and function, regulating both the generation of gut-homing precursors and the specialized functions of DC within the gut environment.
RESULTS

Identification of a phenotypically unique a4b7 þ DC subset in vivo
In studies of DC subsets expressing B220, we discovered a subset of B220 þ CD11c int DCs that expresses the a4b7 integrin, a homing receptor that mediates lymphocyte recruitment into the intestinal wall through interaction with the mucosal vascular addressin MAdCAM1 13 (Figure 1a ; Supplementary Figure S1a online). a4b7 þ B220 þ DCs are found in secondary lymphoid tissues and the BM, and are particularly prominent among the B220 þ DCs in the gut-associated MLN and in the small intestine (SI) lamina propia (LP) (Figure 1a ; Supplementary Figure S1a online). These cells are phenotypically distinct from previously described peripheral or BM DC populations or precursors, including splenic cDCs, BM CCR9 þ pDCs, common DC progenitors (CDPs), and pre-cDCs (Supplementary Figure S1b and c online). We took advantage of an Fms-like tyrosine kinase 3 ligand (Flt3L)expressing B16 melanoma to expand DC subsets in vivo with minimal alterations in their phenotypic or functional capabilities for homing and adoptive transfer studies. 14 The a4b7 þ B220 þ DCs were dramatically expanded in Flt3Ltreated mice, suggesting a proliferative or progenitor potential ( Figure 1b ). We refer to them hereafter as pre-mDCs, short for pre-mucosal DCs.
We hypothesized that, by virtue of their expression of a4b7, pre-mDCs might home efficiently from the blood into the gut wall. Pre-mDCs were sorted from lymphoid tissues of Flt3Ltreated B6.CD45.2 mice. Localization in vivo was assessed 3 days after intravenous transfer into congenic B6.CD45.1 recipients. Pre-mDCs preferentially homed to the SI LP ( Figure 1c ). Preferential homing of pre-mDCs to the SI LP and colon was also apparent in shorter-term (12 h) homing studies (data not shown).
Pre-lDCs give rise to CCR9 þ pDCs and to CD103 þ cDCs in vitro
To assess the progenitor potential of pre-mDCs, we sorted them from BM and cultured them in vitro with total BM cells taken from CD45 allotype congenic mice as feeder cells (Figure 2a ).
In some experiments, we also used pre-mDCs sorted from the BM of Flt3L-treated mice; these cells are phenotypically similar to normal BM pre-mDCs, the classical CCR9 þ pDC markers PDCA1, Siglec H, and Ly6c are downregulated, not unlike the surface phenotype of pre-mDCs in normal spleen (see Figure 4a ). Cells were cultured with recombinant Flt3L and their progeny were analyzed by flow cytometry after 3-6 days. By days 3-4, the cultures contained three prominent and phenotypically distinctive pre-mDC-derived populations ( Figure 2b and c): CCR9 þ pDCs, which retained high levels of B220 and intermediate expression of CD11c; CD103 þ DCs that were a4b7 À CCR9 À B220 À and CD11c þ , essentially a cDC phenotype; and a population of a4b7 þ pre-mDC-like cells whose phenotype (lower B220 and slightly higher CD11c levels than starting pre-mDCs) appeared transitional between that of BM pre-mDCs and cDCs. In fact, a fraction of the a4b7 þ DC had upregulated CD103. By day 6, pre-mDC-derived progeny were mostly CD103 þ cDC (70-80%, N43) ( Figure 2c ). However, the absolute numbers of all three subsets peaked on day 3 and decreased by day 6, suggesting limited life span of pre-mDC and their progeny in vitro (Supplementary Figure S2a online) . Similar results were seen whether pre-mDCs were from normal or Flt3L-treated mouse BM (Figure 2b and c) . Consistent with prior studies of Flt3L-driven in vitro BM-derived cDC, pre-mDC progeny in vitro did not express surface CD8a (data not shown). The results demonstrate that pre-mDCs can give rise rapidly to both classical CCR9 þ pDCs and to CD103 þ cDCs. We were unsuccessful in efforts to evaluate pre-mDC development at the clonal level and therefore cannot exclude the possibility that distinct pDC and cDC precursors exist within the gut-tropic pre-mDC pool.
Pre-lDCs give rise to CCR9 þ pDCs and to CD103 þ cDCs in vivo
We next assessed the development of pre-mDC in vivo in a homeostatic setting. We sorted pre-mDCs from Flt3L-treated B6.CD45.2 mice and injected them into congenic B6.CD45.1 recipients. Recipient mice were killed on day 4 or 7. On day 4 after transfer, both cDCs and CCR9 þ pDCs were observed among CD45.2 þ pre-mDC-derived progeny cells in the spleen, small intestine, and lung. In the intraepithelial lymphocytes (IEL), CCR9 þ pDCs (CD11c int B220 þ CCR9 þ ) predominated among pre-mDC-derived cells (Figure 3a , left). In the SI LP, a subset of transferred cells maintained the pre-mDC phenotype (a4b7 þ , CD103 À ), with some showing reduced B220 expression ( Figure 3a , right). Pre-mDC progeny in the SI LP and in other tissues analyzed were mainly CD103 þ cDCs (mucosal tissues) or CD8a þ cDC (in the spleen) on both days 4 and 7 (Figure 3b and data not shown). By day 7, most pre-mDCderived CCR9 þ pDCs and pre-mDC themselves had disappeared from all tissues, suggesting rapid turnover of pre-mDC-derived CCR9 þ pDCs and a limited self-renewal capacity of pre-mDCs. Consistent with their preferential homing to the SI LP, a higher percentage of cDCs in the SI LP than in the spleen or the lung originated from pre-mDCs ( Figure 3c ). Similar results were seen in lethally irradiated recipients (Supplementary Figure S2b online). Intestinal CD103 þ cDCs comprise two distinct subsets: CD11b þ and CD11b À . Pre-mDCs gave rise to both CD103 þ CD11b À and CD103 þ CD11b þ intestinal cDCs in the SI LP ( Figure 3b and d). The intestinal CD103 þ CD11b À cDCs are developmentally related to the splenic CD8a þ CD11b À cDCs, as their development depends on common transcription factors. 15, 16 No developmental equivalent of the intestinal CD103 þ CD11b þ cDCs have been identified in the spleen. Most of the pre-mDC-derived CD8a þ CD11b À cDCs in the spleen expressed a low level of CD103 (data not shown). Bogunovic et al. 2 have shown that migratory pre-cDC (Lineage À CD11c þ MHCII À CD135 þ Sirpa low ) can also give rise to CD103 þ cDC in the SI LP. When co-transferred with pre-cDC, pre-mDC are 7-to 10-fold better than pre-cDC at giving rise to cDC in the SI LP on a per cell basis (Supplementary Figure S2c online). This is not surprising because unlike pre-mDC, pre-cDC do not express gut-specific homing receptors and thus are not primed to repopulate the intestines (see Supplementary Figure S1c online). Few pre-mDC-derived cells were seen in the MLN 4 days after transfer but by day 7, significant fractions of CD103 þ CD11b À and CD103 þ CD11b þ cDCs in the MLN were derived from pre-mDCs ( Figure 3d ). Given preferential homing of pre-mDC to the LP rather than the MLN, pre-mDCs likely differentiate Pre-μDCs sorted from Flt3L-treated BM Day 3
Post-sort purity into CD103 þ mucosal DCs in the gut wall and subsequently migrate to the MLN. This is consistent with the known migratory behavior of small intestine CD103 þ cDCs. 17 Importantly, pre-mDC-derived cDCs (CD11c þ MHCII þ B220 À CD103 þ CD11b þ or CD11b À ) in GALT displayed the characteristic aldehyde dehydrogenase (ALDH) activity of endogenous CD103 þ gut cDCs: B50% of pre-mDC-derived cDCs in the MLN stained strongly with Aldefluor ( Figure 3e ), a fluorogenic substrate used to detect ALDHs important in the metabolism of retinal to RA. 18 In contrast, pre-mDCs in the BM (data not shown) and pre-mDC-derived splenic cDCs did not display ALDH activity (Figure 3e ). Thus, pre-mDCs give rise to both CD11b þ and CD11b À subsets of CD103 þ cDCs in the SI LP and acquire mucosal characteristics in response to the intestinal or GALT environment. Furthermore, antibody blockade of a4b7 during pre-mDC transfer drastically reduced the number of pre-mDC-derived cDC in the LP, but not in the spleen or lung (Figure 3f ), consistent with an important role for a4b7-mediated homing in the pre-mDC contribution to the intestinal DC pool.
CD11c int B220 þ DCs were comprised of a4b7 þ pre-mDCs, CCR9 þ pDCs, and a subset of a4b7 À CCR9 À (double- Figure S3b online and Figure 2b and c). In contrast, sorted CCR9 þ pDCs retained their phenotype in culture, indicating that these cells were terminally differentiated (data not shown). Like pre-mDCs, upon longer culture DN DCs developed into cDCs, including CD103 þ cDC, although cDC development from DN DCs was delayed relative to that from pre-mDCs ( Supplementary Figure S3c online). When transferred into normal or irradiated recipients, DN DCs were slightly less efficient than pre-mDC at generating cDCs in lymphoid tissues and did not preferentially contribute to intestinal vs. splenic cDC populations at the time points examined (days 5-7, Supplementary Figure S3d online). These results suggest that pre-mDCs arise from DN DCs in the BM, but that pre-mDCs may be more developmentally primed to migrate and reconstitute peripheral tissues, especially the intestinal tract, than are DN DCs.
Intestinal pre-lDCs display a transitional phenotype but retain progenitor activity
Pre-mDCs are most highly represented within the GALT and SI LP of those tissues evaluated. Compared with BM pre-mDCs, pre-mDCs in the LP displayed higher expression of CD11c, but lower or no expression of pDC markers including B220, PDCA1, Ly6C, and Siglec H (Figure 4a) . LP pre-mDCs also appeared more mature than their BM counterparts, with higher MHCII, CD11b, a4b7, and CCR6 expression but similar CD80 and CD86 co-stimulatory molecule expression ( Figure 4a) . Splenic pre-mDCs had an intermediate phenotype (Figure 4a ). When cultured with Flt3L and total BM cells, SI LP pre-mDCs retained the ability to generate CD103 þ cDCs; but they displayed little or no potential to give rise to pDCs (Figure 4b) .
Furthermore, B30% of LP pre-mDC expressed proliferating cell nuclear antigen and transferred pre-mDC can still be detected 4 days after transfer, suggesting that pre-mDCs can proliferate locally in the SI LP (data not shown and Figure 3a ). We conclude that pre-mDCs in the LP retain cDC progenitor activity, but have a transitional phenotype likely reflecting their programmed development into CD103 þ intestinal cDCs.
RA controls pre-lDC development in the BM
We next asked whether RA regulates the development of a4b7 þ pre-mDCs from BM progenitors. Addition of RA to cultures of total BM dramatically increased the frequency of pre-mDCs among total progeny cells at the expense of CCR9 þ pDCs and DN DCs (Figure 5a and b and data not shown). Consistent with a requirement for RA signaling through its nuclear receptor RARa, pre-mDC generation was also enhanced by the selective RARa agonist AM580 (Figure 5a and b; Supplementary Figure S4a online). When cultured with delipidated serum, which is free of retinoids, fewer pre-mDC were generated. When RA or AM580 was added to the culture with delipidated serum, pre-mDC generation was enhanced (Supplementary Figure  S4b online). Furthermore, addition of the pan-RAR inverse agonist BMS493 or pan antagonist LE540 inhibited pre-mDC development in vitro (Figure 5a and b and data not shown). Like pre-mDC found in the BM in vivo, pre-mDC generated in vitro with or without RAR signaling are mostly CD103 À (Supplementary Figure S4c online) . To assess the involvement of proliferation in these effects, we labeled BM with carboxyfluorescein diacetate succinimidyl ester (CFSE) prior to culture. Under control conditions or with the RAR antagonist, a significant fraction of developing CCR9 þ pDCs were derived from cells that had divided, but RA or the RARa agonist almost completely eliminated this population of previously divided CCR9 þ pDCs ( Figure 5) . Given the limited self-proliferative potential of CCR9 þ pDCs, it is likely that RAR signaling directly inhibits CCR9 þ pDC development from progenitors in the BM. In contrast, RA signaling enhanced the percentage of a4b7 þ pre-mDCs arising from dividing cells (Figure 5c ). Thus, RA regulates the generation of pre-mDC.
Manipulation of the RAR signaling pathway had similar effects on pre-mDC development in vivo. Mice treated with RA and AM580 displayed an increase in pre-mDC frequency in the BM, consistent with our in vitro observations. In contrast, treatment with BMS493 reduced the frequency of pre-mDCs ( Figure 5d ). More importantly, pre-mDCs were also significantly reduced in the BM of mice fed a vitamin A-deficient diet compared with mice fed a control diet (Figure 5d ). We conclude that vitamin A and its metabolite RA regulate the development of a targeted precursor for intestinal DCs.
DISCUSSION
We have identified a migratory common DC precursor that preferentially homes to the gut wall and gives rise to intestinal DCs, especially CD103 þ subsets. Pre-mDCs have an immature phenotype and share phenotypic features with CCR9 þ pDCs, including expression of pDC markers such as PDCA1, Siglec H, Ly6C, and B220, but are distinguished from CCR9 þ pDCs by differential trafficking receptor expression and by their developmental potential. Pre-mDCs express a4b7 but not CCR9 and proliferate and differentiate into cDCs and CCR9 þ pDCs in vitro and in vivo, whereas conventional CCR9 þ pDCs are a4b7 À and are terminally differentiated. BM pre-mDCs are closely related to and can arise from CD11c int B220 þ CCR9 À a4b7 À DN DCs.
Development of pre-mDCs in the BM is regulated by RA. Treatment of BM cultures with RAR agonists increased and RAR antagonists decreased the frequency of pre-mDCs. All trans-RA, a pan-RAR agonist, and AM580, an RARa-specific agonist, had similar effects on pre-mDC development, suggesting that modulation of RAR signaling in the BM is primarily through RARa. RAR signaling had a similar modulating effect on pre-mDC development in vivo. Vitamin A deficiency, which leads to reduced circulating retinol, 11 reduced the number and frequency of pre-mDCs in the BM. Similarly, systemic treatment of mice with the pan-RAR inverse agonist BMS493 reduced pre-mDC, whereas intraperitoneal administration of all trans-RA or the RARa agonist AM580 increased the frequency and number of pre-mDCs dramatically. RA regulates hematopoietic progenitor development, and modulation of RARa/RXR signaling regulates hematopoietic stem cell (HSC) differentiation, proliferation, and self-renewal. [19] [20] [21] Furthermore, RA modulates neutrophil differentiation from myeloid progenitors under steady-state conditions. 22 While BM pre-mDCs lack ALDH activity (as indicated by Aldefluor assay; data not shown), subsets of BM hematopoietic cells, including HSCs, express RALDHs, 21,23 providing a potential source for RA generation from retinol within the local BM environment.
Earlier studies showed that RA regulates cDC function within the intestinal LP and GALT. RA induces the RALDH gene Aldh1a2 in intestinal DCs. 10 RALDH allows intestinal cDCs to convert retinal to RA, creating a positive feedback loop and also allowing GALT DCs to present RA along with antigen to T cells. RA in turn induces T-cell expression of the guthoming receptors a4b7 and CCR9. In this manner, T cells responding to gut antigens are programmed to traffic back to the intestines. 11 Interestingly, although RA also induces a4b7 expression on developing pre-mDCs, it does not induce CCR9 expression. Indeed, expression of a4b7 and CCR9 is mutually exclusive among B220 þ CD11c int DCs, and RA actually suppresses the development of CCR9-expressing pDCs in our in vitro and in vivo models. Thus, the signaling pathways that control expression of these trafficking receptors must differ in DCs and lymphocytes. BM pre-mDCs do not display intrinsic ALDH activity, but we show that their CD103-expressing cDC progeny upregulate ALDH activity within the gut environment. Furthermore, pre-mDC-derived splenic cDC and CD103 þ CD11b À intestinal cDC express CD8a in vivo but pre-mDCderived CD103 þ cDC do not express CD8a in vitro. This suggests that the in vivo tissue environments of the spleen or LP must comprise additional factors or stimuli not present in our in vitro culture system.
We focused primarily on cDC progeny in our analyses, even though pre-mDCs rapidly differentiated into CCR9 þ pDCs as Sorted LP pre-μDC Day 3 well both in vitro and in vivo. Pre-mDC-derived pDCs were especially abundant relative to pre-mDC-derived cDCs in the BM and the IEL compartments of the gut wall of adoptive recipients. This distribution parallels the characteristic homeostatic representation of DC subsets in these sites, where classical CCR9 þ pDCs significantly outnumber cDCs (whereas cDCs predominate in most other tissues). Although pre-mDCderived pDCs generated in the BM or other tissues can likely home to the gut after upregulation of CCR9, pre-mDCs may also be able to generate pDCs locally in the gut after entry from the blood. Importantly, in the gut, pre-mDC-derived pDCs appeared rapidly and then disappeared from the recipient IEL compartment within 5-6 days, whereas donor-derived intestinal cDCs remained readily detectable for at least 10 days after pre-mDC transfer. Overall, the tissue-and time-dependent representation of pre-mDC-derived pDCs and cDCs likely reflects multiple factors including environmental effects on pre-mDC differentiation into pDCs vs. cDCs, intrinsic and/or environment-specific differences in the survival and proliferation of progeny pDCs vs. cDCs, and a limited self-renewal potential of pre-mDCs. Another potential factor is the apparent progressive loss of pDC potential after pre-mDCs enter peripheral tissues, as evidenced by the inability of pre-mDCs from the SI LP to generate pDCs in culture.
In the BM, pre-mDCs are a minor subset of the B220 þ CD11c int DCs: The majority of B220 þ DCs are CCR9 þ pDCs and CCR9 À a4b7 À DN DCs. Importantly, DN DCs depleted of pre-mDCs gave rise to pre-mDCs in culture, and thus contain precursors for both pre-mDC and CCR9 þ pDC. DN DC conversion into CCR9 þ pDC and a4b7 þ pre-mDC phenotypes occurred rapidly, within 2 days, and did not require cell division (data not shown). DN DCs also gave rise to cDCs, including CD103 þ cDCs, in longer-term culture. These findings are consistent with the reported ability of splenic and BM CD11c int B220 þ CCR9 À DCs to give rise to cDCs 24, 25 (and see next paragraph). Moreover, culture of classical CD11c À CDPs with Flt3L also led to production of DN DCs and pre-mDCs, as well as to pDCs and cDCs (data not shown). In the simplest interpretation, our data suggest a linear model in which BM progenitors such as the CDP and possibly early progenitors such as the macrophage, DC progenitor (MDP) give rise to CD11c int B220 þ DN DCs, which in turn differentiate into pre-mDCs that rapidly exit the marrow and home to the gut to replenish intestinal DCs (Supplementary Figure S5 online). However, given the emerging appreciation of nonlinear developmental sequences in hematopoiesis and of the malleability of progenitors in response to environmental signals, [25] [26] [27] we cannot exclude other pathways to pre-mDC development.
The gut-homing ability of pre-mDC, their capacity to differentiate into pDC as well as cDC, and their preferential contribution to intestinal DC distinguishes them from other migratory DC precursors. BM pre-cDCs (lineage À B220 À CD11c þ MHCII À CD135 þ Sirpa low cells) described by Liu et al. 28 and splenic pre-cDC (CD11c int MHCII À CD45RA low CD43 int Sirpa int ) described by Naik et al. 29 have a more restricted developmental potential, contributing to peripheral cDCs but not pDCs. Moreover, although pre-cDCs give rise to CD103 þ intestinal DCs as well as other peripheral DC populations, they lack specialized gut-homing ability (they are a4b7 and CCR9 negative). In fact, in our co-transfer experiments, pre-mDC are 7-to 10-fold better than pre-cDC at contributing to intestinal cDC on a per cell basis. Pre-mDC are more closely related phenotypically to recently identified ''CCR9 À pDC-like precursors,'' a common DC precursor which (like pre-mDC and the DN DC population studied here) is B220 þ and expresses intermediate levels of CD11c: Schlitzer et al. 25, 30 showed elegantly that although these CCR9 À pDC precursors can be induced to differentiate into cDC by GM-CSF or microenvironmental influences, they preferentially give rise to pDCs. This contrasts with the preferential cDC development displayed by pre-mDCs. Phenotypically, CCR9 À pDC precursors are defined as SiglecH hi PDCA1 hi CCR9 À CD11c þ and B220 þ ; 25, 30 as such they comprise a small subset of pre-mDC (the PDCA1 hi SiglecH hi fraction), as well as a large fraction of DN DCs enriched for high levels of expression of the pDC differentiation antigens PDCA1 and SiglecH. We have shown that, in contrast to pre-mDC but similar to Schlitzer's pDC precursors, CCR9 À a4b7 À DN DCs preferentially give rise to pDCs at early time points. We propose therefore that the Lin À B220 þ C11c int CCR9 À population of BM cells comprises a diverse precursor pool for peripheral DC subsets, in which functional precursors with a preference towards pDC development are enriched in the PDCA1 hi SiglecH hi a4b7 À CCR9 À pDC-like subset; whereas precursors biased towards development into intestinal CD103 þ DCs are enriched in the guthoming a4b7 hi pre-mDC population. Indeed, pre-mDC themselves may well be heterogeneous in potential: we cannot exclude the possibility that some pre-mDC are clonally committed to pDC vs. cDC development, or indeed that B220 þ C11c int BM DC, including gut-tropic pre-mDC, are composed of distinct subsets of committed pDC vs. cDC precursors. This pool of B220 þ DC precursors was not recognized in earlier studies that included B220 as a marker of exclusion in a ''lineage negative'' sort gate. 28 In the BM, pre-mDCs are a minor subset of this pool, which may reflect programming for rapid exit from the marrow to seed the gut wall. In addition to these CD11c þ migratory precursors, earlier progenitors, including CD11c À CDPs and even pluripotent HSCs, may be able to seed peripheral tissues and contribute to tissue DC populations. 31, 32 The rates of generation and exit of each of these distinctive DC precursors, their relative contributions to CD103 þ CD11b À vs. CD103 þ CD11b þ intestinal DC and to other peripheral DC populations, and their relative importance in homeostatic vs. inflammatory settings remain to be determined.
The recruitment of blood leukocytes requires adhesion and chemoattractant receptors to mediate endothelial adhesion, arrest, and subsequent diapedesis. 33 Pre-mDCs express a4b7, an integrin receptor for the mucosal vascular addressin MAd-CAM1, on gut postcapillary venules, and blockade of a4b7 prevents pre-mDCs from contributing to intestinal DC populations. It is unclear which chemoattractant receptors are involved in this process. CCR9 is an important chemokine receptor for T and B lymphocytes and in CCR9 þ pDC homing to the SI. However, pre-mDCs do not express CCR9. Moreover, blocking antibody to the CCR9 ligand CCL25 had no effect on pre-mDC-derived cDC in the SI, and pre-mDCs from CCR9knockout mice homed to and gave rise to CD103 þ cDCs in the SI as efficiently as wild-type cells (data not shown). Although BM pre-mDCs express minimal CCR6, CCR6 is upregulated on pre-mDC in the SI LP, thus CCR6 might contribute to pre-mDC homing. Pre-mDCs also express CCR5 and CXCR3 that could participate in gut homing. On the other hand, pre-mDC lack the lymphoid organ trafficking receptor CCR7, consistent with their inability to home well to MLNs in spite of a4b7 expression.
In conclusion, we identify a gut homing common DC precursor whose development in BM is regulated by RA and impaired in vitamin A deficiency. Pre-mDCs can generate cDC and CCR9 þ pDC, but more efficiently give rise to CD103 þ cDC populations in the small intestines. Gut-specific homing of DC precursors may allow targeted replacement of intestinal DCs as a function of ongoing tissue-specific immune requirements.
METHODS
Mice. C57Bl/6.CD45.2 (B6.CD45.2) and C57Bl/6.CD45.1 (B6.CD45.1) mice were originally purchased from Jackson Laboratory (Bar Harbor, ME) and were maintained and bred in specific pathogen-free conditions in the animal facility in Veterans Affairs Palo Alto Health Care Systems (VAPAHCS). To generate B16/Flt3L-injected mice, 5 million B16/Flt3L cells were injected subcutaneously near the neck and animals were killed 11-14 days later. All animals were used in accordance with the guidelines set forth by the animal committee of VAPAHCS. Vitamin A-deficient and control mice were generated as described. 11 In some experiment, mice were i.p. injected with BMS493 (25 mM in DMSO) at 1 ml/g of weight in 25 ml of olive oil. Control animals received the same amount of DMSO in olive oil. All trans-RA was made into suspension in olive oil at 25 mg/ml and injected i.p. at 125 mg/g of weight, control animals received olive oil. AM580 was dissolved in DMSO at a concentration of 40 mg/ml and injected i.p. at 1 ml/g of weight with 100 ml of olive oil; control animals received the same amount of DMSO in olive oil.
Flow cytometry. Samples (single-cell suspensions) were first blocked with FACS buffer (HBSS with 2% FCS) containing 100 Â dilution of antibody against mouse FcgIII/II receptor (BD Bioscience, San Jose, CA) and rat serum to prevent nonspecific binding of monoclonal antibodies. The following antibodies were used for staining: CD3-Cell isolation from tissues. Femurs and tibias were collected and crushed using a 5-ml syringe. Bone fragments were removed by filtering through a wire mesh to isolate BM cells.
Spleens, inguinal, auxiliary, and brachial lymph nodes (LNs) were isolated and digested with RPMI media containing 5% FCS, 500 unit/ml of collagenase IV (Worthington Biochemical, Lakewood, NJ) and 1 unit/ml of DNaseI (Sigma, St Louis, MO) for 30 min at 371C and made into single-cell suspension.
Lungs were perfused with 25 ml of phosphate-buffered saline (PBS) and cut into small pieces (B1-2 mm) and digested as were spleen and LNs.
Full-length SI (with Peyer's Patches removed) was cut open longitudinally and rinsed twice in HBSS (without Ca 2 þ and Mg 2 þ ) with 2% FCS and cut into small pieces. To isolate IEL, the cut SI was incubated twice in 10 ml of 2% HBSS containing 15 mg/100 ml dithiothreitol at 371C for 20 min, twice, and supernatant containing IEL was collected after each incubation. Residual tissues were digested in 10 ml RPMI containing 5% FCS and 0.5 mg/ml of collagenase IV (Sigma C2139) at 371C for 30 min, three times. Supernatant containing LP cells was collected. Mononucleated cells from the IEL and LP supernatant were isolated by gradient separation with 40 and 75% percoll solutions (GE, Pittsburgh, PA, 17-0891-01) at 2,000 RPMI for 20 min at room temperature. Cells of interest were located at the interface. When young mice (10-16 days of age) were used, Peyer's Patches were not removed because they are not clearly visible at this age.
Cell sorting. To sort pre-mDCs and DN DCs from normal and Flt3Ltreated mice, BM cells were isolated as described above and enriched by magnetic-activated cell sorting using the pan-DC kits from Miltenyi (Auburn, CA). The cells were then sorted on Aria II or III (BD) for Lineage (CD3, CD19, NK1.1)-CD11c int B220 þ a4b7 þ CCR9 À pre-mDC and Lineage À CD11c int B220 þ a4b7 À CCR9 À DN DC.
Adoptive transfer. For transfer into lethally irradiated recipients, B6.CD45.1/45.2 F1 mice were given full-body irradiation with a lethal dose of 900 rads total from a 131 Cs source at two doses (4 h apart, 450 rads each). Irradiated mice were given total BM (CD45.1) and sorted pre-mDCs (CD45.2 or vice versa) at a ratio of 10:1 (5 Â 10 6 total BM and 0.5 Â 10 6 sorted pre-mDC). Mice were kept on antibiotic water until they were killed on days 4,7,10, or 14. Adoptive transfer into normal recipients was performed the same way except recipient mice were not irradiated and received only sorted pre-mDC (1-3 Â 10 6 ). For homing experiments, 3 Â 10 6 sorted pre-mDCs were transferred into each congenic recipient.
Blocking experiments. Sorted pre-mDC from Flt3L-treated mice were pre-blocked with 250 mg of anti-a4b7 antibody made in house (DATK32) or isotype control (Rat IgG2a) in 200 ml PBS for 10 min at room temperature before injection. Subsequently, recipients received blocking antibody or isotype control every 12 h via intraperitoneal injection until mice were killed. All cell transfers were done via retroorbital injection.
In vitro culture. Pre-mDCs and DN DCs were sorted from BM (or SI LP for pre-mDC in some experiments) from normal or Flt3L-treated mice and cultured with congenic total BM cells at a density of 3-5 million cells/ml, 200 ml/well in flat-bottom 96-well plate in complete RPMI media (10% FCS, 1 Â penicillin/streptomycin) supplemented with 100 ng/ml recombinant Flt3L. Media were changed on day 3.
Total BM cells were cultured in complete media with normal FCS or delipidated FCS with 100 ng/ml of rFlt3L in the presence of 1 nM of ATRA, 10 nM of AM580, or 100 nM of BMS493. Media were changed on day 3. CFSE labeling. Total BM cells were incubated with 1 mM of CFSE at a density of 10E6 cells/ml in PBS for 10 min at 371C and washed by incubating in complete media for 5 min at 371C.
Analysis of ALDH activity. ALDH activity in each cell was analyzed using Aldefluor Staining Kit (StemCell Technologies, Vancouver, BC, Canada) as per the manufacturer's protocol with modifications as previously described. 18 Briefly, cells were suspended in Aldefluor assay buffer containing activated substrate (150 nM) with or without the ALDH inhibitor DEAB (100 mM) at a density of 10E6 cells/ml and incubated in 371C water bath for 30 min. Subsequent surface antigen staining was performed in Aldefluor assay buffer. Cells were immediately analyzed on LSRII analyzer (BD) without fixing.
Statistical analysis. The statistical significance of differences between the two sets of data was assessed by Student's t-test unless stated otherwise.
